Services
Therapeutic Antibody & Protein Development
Therapeutic Antibody & Protein Development
Cell Banking
Cell Line Characterization
Cell Culture Process Development
Purification Development
Formulation Development
Process Development
Analytical & Bioassay Quality Control
Contamination Testing
Biosafety Testing
Lot Release Testing
Stability Analysis
Cell Line Development
Viral Clearance
Preclinical Testing
Efficacy Models
Antibody & Protein Pharmacology
Antibody & Protein Toxicology
Biologics Testing
Bioassay
Structure & Biochemical Characterization
cGMP Manufacturing
IND Regulatory Services
Regulatory Strategy Consulting
Medical Writing & Translation
Pre-IND Meeting
IND Publishing and Submission
Post-IND Maintenance
Modality
Antibody-Drug Conjugate (ADC) Technology
Next CAR-T Therapy Development
T Cell Gene Signature Technology and Analysis
Bifunctional mAb Pair Development
Nano-based NK Engager Development
Immunocytokine Engineering Development
PEG-Modified Cytokine Development
High-Content Multiplexed Cell & Bead-Based Detection
Intratumoral Treg Assay
Predictive Biomarkers Analysis
High-Throughput Antibody Production Platform
Bispecific Antibody (BsAb)
FH-Bind™ Platform
Antibody & Protein Discovery
Target Discovery & Validation
Antibody Discovery
Antibody & Protein Production
Next-IO™ Alzheimer's Disease Therapeutics
Synthetic Gene Circuits for Cancer Immunotherapy - Turning Cancer Cells Against Themselves
Ex Vivo
Immune Reactivity Assessment Service
Cytokine Production Measurement Service
Chemokine Production Measurement Service
Tumor Profiling to Guide Targeted Cancer Therapy
Gut Microbiota-based Diagnostics Platform
Cancer Microbiome Profiling
Cancer Metabolomics Analysis
Brain-Immune-Gut Based Integrative Research
Tumor Energy Metabolism Analysis Services
Tumor Metabolism Characterization
Tumor Metabolic Microenvironment Analysis
Tumor Metabolic Pathway Analysis
Multi-Omic Platform-Guided Tumor Metabolism Characterization
Tumor Cellular Metabolism Assay
Tumor Subcellular Metabolic Analysis
In Vivo
Tumor Metabolism Analysis
Functional Genetic Screening for Tumor Metabolism
Gene-Editing-based Metabolic Gene Functional Assessment
Small Molecule Inhibitor-based Metabolic Enzyme Functional Assessment
Human Oncology Imaging Services
Tumor Contrast Imaging Solutions
Photoacoustic Tumor Imaging
Contrast-Enhanced CT Tumor Imaging
Contrast-Enhanced MRI Tumor Imaging
Integrated Solutions for Cancer Immunotherapy Development
Microbiological Test
Targeting Ferroptosis Solutions in Oncology
In Vitro
ADME for Cancer Immunotherapy
Graft-Versus-Host Disease (GVHD) Research Solutions
Cancer Resistance Integrated Solutions
Cytokine Immunotherapy Development
Therapeutic Cytokine Development
Integrated Non-coding RNA Characterization
Integrated Cell Cycle Dysregulation Analysis
Immunophenotyping Services
Cardiotoxicity Analysis & Prevention Solutions
Antibody-directed Enzyme Prodrug Therapy (ADEPT) Solutions
Custom Gene Circuit Development
Integrated Carcinogenic Factor Analysis
Integrated Genome Instability & Mutation Analysis
Comprehensive Oncogene & Tumor Suppressor Profiling
Comprehensive Cancer Epigenetic Mapping
Integrated Tumor Angiogenesis & Vascular Evaluation
Products
Oncology Cell Lines
Cancer Cell Lines
Reporter Cell Lines
Luciferase Cell Lines
EGFP Cell Lines
Dual Labeled Cell Lines
Gene Editing Cell Lines
KO Cell Lines
Knockin Cell Lines
Knockdown Cell Lines
Primary Cells
Stem Cells
Drug Resistant Cells
OncoImmune Cells
Oncology Kits
Consumables
Tumor Marker Kits
Oncology Assay Tools
Metabolomics Analysis Tools
Animal Models
Synthetic Gene Circuit Cells
Cell Transport Capsule Kits
Programs
COVID-19 Recovered Patient-Derived Anti-SARS-CoV-2 Therapeutic Antibody Development
Next-IO™ Macrophages-related Therapeutics
Next-IO™ Anti-CD11b Therapeutic Monoclonal Antibody Program
Next-IO™ IL-4R Therapeutic Fusion Protein Program
Next-IO™ COX2 Therapeutic Monoclonal Antibody Program
Next-IO™ Ang-2 & VEGF Therapeutic Bispecific Antibody Program
Next-IO™ Anti- SIRPα Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-iNOS Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-SOCS3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD163 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-SR-B1 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-TGM2 Therapeutic Monoclonal Antibody Program
Next-IO™ VEGF × DLL4 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-DLL4 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-DLL3 Therapeutic Monoclonal Antibody Program
Next-IO™ SIRPα-Fc Fusion Protein Program
Next-IO™ Anti-Siglec-10 Therapeutic Monoclonal Antibody Program
Next-IO™ Chemokines and Chemokine Receptors-Related Therapeutics
Next-IO™ Anti-CCL2/CCR2 Axis Targeted Therapeutic Antibody Program
Next-IO™ NK Cell-related Therapeutics
Next-IO™ Fusion Proteins of NKG2D Program
Next-IO™ Anti-sMIC Monoclonal Antibody Program
Next-IO™ Anti-CD48 Monoclonal Antibody Program
Next-IO™ Anti-2B4 Monoclonal Antibody Program
Next-IO™ Anti-HLA-G Monoclonal Antibody Program
Next-IO™ Anti-KIR2DL4 Monoclonal Antibody Program
Next-IO™ Anti-KIR2DL1-3 Monoclonal Antibody Program
Next-IO™ Anti-CD94/NKG2A Monoclonal Antibody Program
Next-IO™ Anti-PVR Monoclonal Antibody Program
Next-IO™ Anti-CD96 Monoclonal Antibody Program
Next-IO™ Anti-CD16 (FcgRIIIA) IgG Program
Next-IO™ Anti-LILRB1 Monoclonal Antibody Program
Next-IO™ Anti-KLRG1 Monoclonal Antibody Program
Next-IO™ Anti-Cadherin Monoclonal Antibody Program
Next-IO™ Anti-LLT1 Monoclonal Antibody Program
Next-IO™ Anti-NKRP1A Monoclonal Antibody Program
Next-IO™ Targeting Sialic Acid Program
Next-IO™ Anti-Nectin-2 Monoclonal Antibody Program
Next-IO™ Tumor Associated Antigens
Next-IO™ Anti-CD73 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPVI Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Phosphatidylserine Monoclonal Antibody Program
Next-IO™ Anti-CD47 Therapeutic Monoclonal Antibody Program
Next-IO™ CD47 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-Ang2 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-BCMA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD123 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × PD-L1 Dual-Targeted Therapeutic Fusion Protein Program
Next-IO™ CD47 × CD19 Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × MSLN Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × EGFR Dual-Targeted Therapeutic Fusion Protein Program
Next-IO™ TGF-β × PD-L1 Bi-Functional Therapeutic Fusion Protein Program
Next-IO™ Anti-GPC3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPC3 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-GPA33 × CD3 Bispecific DART Protein Program
Next-IO™ Anti-GPRC5D × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-GPC3 Therapeutic CAR-T Cell Program
Next-IO™ Anti-GPC3 Therapeutic CAR-NK Cell Program
Next-IO™ Anti-MUC16 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CDH3 × CD3 Bispecific DART Protein Program
Next-IO™ Anti-PSMA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-SSTR2 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-MSLN Therapeutic Fusion Protein Program
Next-IO™ Anti-MSLN × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD47 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD47 × CD20 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-PD-L1 × 4-1BB Therapeutic Bispecific Antibody Program
Next-IO™ Anti-PD-L1 × 4-1BB Therapeutic Bispecific DART Program
Next-IO™ Anti-CD24 Monoclonal Antibody Program
Next-IO™ HER3 Therapeutic Monoclonal Antibody Program
Next-IO™ LAG-3 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ LAG-3 x CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ LGR5 Therapeutic Monoclonal Antibody Program
Next-IO™ MHC I:LILRB2 Axis Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-LAG-3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-YTHDF1 Therapeutic Monoclonal Antibody Program
Next-IO™ c-MET x CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ CD22 × CD19 Therapeutic CAR-T Program
Next-IO™ CD22 Therapeutic CAR-T Program
Next-IO™ CTLA-4 x OX40 Therapeutic Bispecific Antibody Program
Next-IO™ GITR x CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ HER2 x HER3 Therapeutic Bispecific Antibody Program
Next-IO™ PAUF Therapeutic Monoclonal Antibody Program
Next-IO™ PD-L1 x TIM-3 Therapeutic Bispecific Antibody Program
Next-IO™ PD-1 x CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ PSCA x CD3 Therapeutic Bispecific Antibody Program
Next-IO™ 4-1BB × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ A2AR Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Galectin-3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPC3 Therapeutic Vaccine Program
Next-IO™ T Cell-Related Therapeutics
Next-IO™ Anti-FGL1 Monoclonal Antibody Program
Next-IO™ Anti-FGL2 Monoclonal Antibody Program
Next-IO™ Anti-Siglec-15 Monoclonal Antibody Program
Next-IO™ Anti-TIM3 Monoclonal Antibody Program
Next-IO™ Anti-4-1BB Monoclonal Antibody Program
Next-IO™ Anti-CD19 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD27 Monoclonal Antibody Program
Next-IO™ Anti-CD40L Monoclonal Antibody Program
Next-IO™ Anti-GITR Monoclonal Antibody Program
Next-IO™ Anti-ICOS Monoclonal Antibody Program
Next-IO™ Anti-TMIGD2 Monoclonal Antibody Program
Next-IO™ Anti-HVEM/TNFRSF14 Monoclonal Antibody Program
Next-IO™ Anti-VISTA Monoclonal Antibody Program
Next-IO™ Anti-PD1 × TIM3 Bispecific Antibody Program
Next-IO™ Anti-TIGIT Monoclonal Antibody Program
Next-IO™ Anti-BTLA Monoclonal Antibody Program
Next-IO™ Anti-CD160 Monoclonal Antibody Program
Next-IO™ Anti-CTLA-4 × CD40 Combination Antibody Program
Next-IO™ Anti-PD-L1 × CD28 Bispecific Antibody Program
Next-IO™ Anti-ROR1 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD20 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD226 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD96 Therapeutic Monoclonal Antibody Program
Next-IO™ ICOS × PD-1 Therapeutic Bispecific Antibody Program
Collaborations
Company
About Us
Contact
Careers
Events
Service
Product
Search
Home
Products
Oncology Kits
Xylidine Ponceau, C.I. 16150
Inquiry
Datasheet
CAT#:
ITS-1022-ZP433
Overview
Description
Ponceau 2R, Ponceau de Xylidine, BSC certified stain. For Masson trichrome staining.
Applications
Tissue Stainning
Related Products
Human LFA-1 ELISA Kit, Lot 21AO-861 [Cancer Immune Checkpoint Assay Kit]
(CAT#: IOK-05-P772)
Human CXCL10 ELISA Kit, Lot 21AO-793 [Cancer Immune Checkpoint Assay Kit]
(CAT#: IOK-05-P704)
EA 65 reagent Pap 3D - Papanicolau
(CAT#: ITS-1022-ZP159)
UNC93B / UNC93B1 Histology Assay Kit
(CAT#: ITS-1122-ZP4169)
FN1 / Fibronectin Histology Assay Kit
(CAT#: ITS-1122-ZP1393)
CHST4 / GlcNAc6ST2 Histology Assay Kit
(CAT#: ITS-1122-ZP786)
CDC20 Histology Assay Kit
(CAT#: ITS-1122-ZP694)
TIMP1 Histology Assay Kit
(CAT#: ITS-1122-ZP3912)
For Research Use Only | Not For Clinical Use
Online Inquiry
Send
